Glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are medications that help the patient to lose weight, give good glycemic control, have shown cardiac benefits, slowed down kidney disease progression and improved the quality of life of patients. This makes these drugs a valuable tool of managing type 2 diabetes and obesity. Many of the patients could avoid bariatric surgery after significant weight reduction. The convenience of weekly injections vs. daily medications or injections has improved the adherence to therapy also. GI side effects like Nausea, vomiting, diarrhea, constipation are very common initially. We should start with low dose and up titrate gradually, guide dietary adjustments (small frequent meals) or use temporary anti-nausea medicines. Major barriers to start is cost and injection phobia.

Many patients are themselves asking for these drugs as these help them to control appetite and give noticeable weight loss boosting their self confidence. Many patients share how this has improved their self esteem and quality of life. Many patients who were advised or taking insulin are doing well with lesser dose/no of injections. Patients pain area is also cost of therapy and worry of regaining weight after discontinuation of therapy.